Supernus Pharmaceuticals, Inc. (SUPN) News Headlines

▮ More

Date

Headline

11/6/2019 12:49:27 AM NXTC Catapults To New High, SUPN Fails Phase 3 Trial, PTLA Delivers Strong Q3

3/29/2019 1:50:34 AM ARDS On The Move, GLPG Reports Positive Data, PRTO Plunges On PATENCY-2 Results

3/28/2019 1:03:03 AM Supernus Pharma Needs Your Attention...

12/6/2018 7:07:36 AM Supernus Announces Positive Results From Two Phase III Studies For SPN-812 In Children With ADHD

12/5/2018 10:16:21 PM Supernus Pharma To Report Phase III SPN-812 Data - Your Attention, Please

11/26/2018 12:56:25 AM Biotech Stocks Facing FDA Decision In December

9/13/2018 4:18:20 PM Supernus To Acquire Biscayne Neurotherapeutics

9/6/2018 3:36:17 PM Supernus Wins Appeal On Oxtellar XR Against TWi

6/27/2018 4:34:27 PM Supernus Pharmaceuticals Elects Carrolee Barlow To Board Of Directors

5/9/2018 1:46:02 AM AKCA Faces FDA Panel Tomorrow, ALDR To Report Data In June, TCMD Riding High

5/8/2018 4:50:58 PM Supernus Pharmaceuticals Q1 EPS $0.49 Vs. $0.19 Year Ago

3/15/2018 6:55:56 AM Supernus Announces Pricing Of $350 Mln Private Offering Of 0.625% Convertible Senior Notes

1/17/2018 8:47:01 PM JUNO Flies On Takeover Rumor, PRTO For Long Haul, SUPN Gaining Strength

11/11/2014 5:32:53 PM Supernus Pharmaceuticals, Inc. (SUPN) Has Raised Its FY14 Revenue Estimate To $115 - $118 Mln From $105 Mln

10/22/2012 7:09:33 AM Supernus Pharma Obtains FDA Approval For Oxtellar XR In Epilepsy - Quick Facts

6/26/2012 9:44:14 AM Supernus Pharma's Epilepsy Drug Gets FDA's Tentative Approval; Shares Soar

6/11/2012 5:20:08 AM Supernus Pharma: Inching Closer To FDA Decision

Older Articles